WeembraceS7.D35Weembrace is the UK arm of the Weembrace Group, a healthcare
company focused on improving access to high-quality, affordable oncology therapies
and supportive care. Our portfolio spans small-molecule oncology medicines
alongside evidence-based onco-nutrition and onco-cosmeceutical solutions, enabling
comprehensive support across the cancer pathway—from treatment to recovery.
Backed by 35+ years in pharmaceutical manufacturing, supply, and hospital
distribution, Weembrace operates a controlled, quality-driven network serving
government and private providers. Our partners’ facilities are WHO-GMP aligned
and operate under robust SOPs covering sourcing, production, packaging, and
logistics. We prioritize regulatory diligence and timely product registrations, working
with local experts to ensure ethical commercialization and consistent quality in each
market.
Weembrace maintains full regulatory compliance across states and
supports large public-sector and institutional demand with dependable service levels.
Internationally, we collaborate across the Middle East, Africa, Europe, and the CIS to
strengthen access to essential oncology care.
At WHX Dubai, Weembrace Karevia is seeking distribution partners, hospital and
pharmacy group buyers, and health-system stakeholders interested in reliable
oncology supply, co-development of formulations, and market-appropriate nutrition
and dermal support for oncology patients. Our goal is consistent: safer, dependable
access to cancer care products at sustainable prices.
